Modified Kigali combined staging predicts risk of mortality in HIV-infected adults in Lusaka, Zambia.

We assessed the utility of the modified Kigali combined (MKC) staging system for predicting survival in HIV-infected Zambian adults in a prospective, longitudinal, open cohort. From 1995 to 2004, HIV-discordant couples (one HIV-infected partner and one HIV-negative partner) were recruited from couples' voluntary counseling and testing centers in Lusaka, Zambia and followed at 3-month intervals. MKC stage, which incorporates clinical stage with erythrocyte sedimentation rate (ESR), hematocrit, and body mass index (BMI), was determined at enrollment. Kaplan-Meier survival and Cox proportional hazard methods were used to calculate median survival and relative hazards. We enrolled 1479 HIV-discordant couples with a combined 7305 person-years of follow-up. Among HIV-infected participants over the 9-year study period, there were 333 confirmed deaths. The time to 50% mortality was 8.5 years with MKC stage 1 and 2 disease compared to 3.7 years with MKC stage 4 disease at enrollment. Survival rates at 3 years were 85% with MKC stage 1 and 2 disease, 74% with MKC stage 3 disease, and 51% with MKC stage 4 disease. A total of 275 HIV-negative partners seroconverted during follow-up. In comparison, survival rates at 3 years were 94% for HIV-negative participants and 92% for participants who seroconverted during follow-up. In multivariate analysis, MKC stage 4 disease (HR = 3.7, 95% CI = 2.7-5.0) remained a strong predictor of mortality. Incorporating ESR, hematocrit, and BMI with clinical staging is a powerful, low-cost tool to identify HIV-infected adults at high risk for mortality.

[1]  W. Fawzi,et al.  C-reactive protein independently predicts HIV-related outcomes among women and children in a resource-poor setting , 2007, AIDS.

[2]  B. Chi,et al.  Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. , 2006, JAMA.

[3]  J. Baeten,et al.  Higher set point plasma viral load and more-severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  B. Lau,et al.  C-reactive protein is a marker for human immunodeficiency virus disease progression. , 2006, Archives of internal medicine.

[5]  P. Wright,et al.  Antiretroviral therapy in a thousand patients with AIDS in Haiti. , 2005, The New England journal of medicine.

[6]  A. Harries,et al.  WHO clinical staging of HIV infection and disease, tuberculosis and eligibility for antiretroviral treatment: relationship to CD4 lymphocyte counts. , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[7]  E. Funkhouser,et al.  Predictors of HIV serostatus among HIV discordant couples in Lusaka, Zambia and female antenatal clinic attendants in Kigali, Rwanda. , 2005, AIDS research and human retroviruses.

[8]  M. Nolan,et al.  The most efficient use of resources to identify those in need of antiretroviral treatment in Africa: empirical data from Côte d'Ivoire's Drug Access Initiative , 2003, AIDS.

[9]  A. Crampin,et al.  Long-term follow-up of HIV-positive and HIV-negative individuals in rural Malawi , 2002, AIDS.

[10]  P. Kaleebu,et al.  Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. , 2002, The Journal of infectious diseases.

[11]  C. Mahé,et al.  HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries? , 2002, AIDS.

[12]  S. Vermund,et al.  Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. , 2001, AIDS research and human retroviruses.

[13]  Hiv Survival,et al.  Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis , 2000, The Lancet.

[14]  R H Lyles,et al.  Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. , 2000, The Journal of infectious diseases.

[15]  J. Whitworth,et al.  The prognostic value of the World Health Organisation staging system for HIV infection and disease in rural Uganda. , 1999, AIDS.

[16]  L A Kalish,et al.  The relative value of CD4 cell count and quantitative HIV-1 RNA in predicting survival in HIV-1-infected women: results of the women's interagency HIV study. , 1999, AIDS.

[17]  C. Luo,et al.  Rapid HIV testing and counseling for voluntary testing centers in Africa. , 1997, AIDS.

[18]  R. Salamon,et al.  Four years of natural history of HIV-1 infection in african women: a prospective cohort study in Kigali (Rwanda), 1988-1993. , 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[19]  E. Hudes,et al.  Classification of HIV Infection and Disease in Women from Rwanda: Evaluation of the World Health Organization HIV Staging System and Recommended Modifications , 1995, Annals of Internal Medicine.

[20]  J. Phair,et al.  Comparison of CD4 cell count by a simple enzyme-linked immunosorbent assay using the TRAx CD4 test kit and by flow cytometry and hematology , 1995, Clinical and diagnostic laboratory immunology.

[21]  J. Koch,et al.  Improvement of the predictive value of CD4 + lymphocyte count by β2‐microglobulin, immunoglobulin A and erythrocyte sedimentation rate , 1993 .

[22]  A Wilkins,et al.  Clinical and laboratory predictors of survival in Gambian patients with symptomatic HIV‐1 or HIV‐2 infection , 1992, AIDS.

[23]  S. Hulley,et al.  Predictors of Mortality among HIV-infected Women in Kigali, Rwanda , 1992, Annals of Internal Medicine.

[24]  R. Chaisson,et al.  Seropositivity for HIV and the development of AIDS or AIDS related condition: three year follow up of the San Francisco General Hospital cohort , 1988, British medical journal.

[25]  P. Rouger,et al.  Sedimentation rate as a predictive marker in HIV infection. , 1988, AIDS.

[26]  A. Harries,et al.  Targeting CD4 testing to a clinical subgroup of patients could limit unnecessary CD4 measurements, premature antiretroviral treatment and costs in Thyolo District, Malawi. , 2006, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[27]  Unaids Aids,et al.  Epidemiological Fact Sheets on HIV/AIDS and Sexually Transmitted Infections , 2004 .

[28]  Mardge H. Cohen,et al.  Erratum: The relative value of CD4 cell count and quantitative HIV-1 RNA in predicting survival in HIV-1-infected women: Results of the women's interagency HIV study (AIDS (1999) 13 (1717-1726)) , 2000 .

[29]  J. Koch,et al.  Improvement of the predictive value of CD4+ lymphocyte count by beta 2-microglobulin, immunoglobulin A and erythrocyte sedimentation rate. The Multicentre Cohort Study Group. , 1993, AIDS.

[30]  J. Margolick,et al.  Natural History of Human Immunodeficiency Virus Type 1 Viremia after Seroconversion and Proximal to AIDS in a Large Cohort of Homosexual Men , 2022 .